The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Liver X receptor agonist treatment significantly affects phenotype and transcriptome of APOE3 and APOE4 Abca1 haplo-deficient mice
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Treatment of different mouse models expressing ApoE4 with the ABCA1 agonist CS-6253 or the LXR agonist T0901317 increases ApoE4 lipidation and reduces ApoE4-driven Aβ accumulation and cognitive deficits.
“the treatment of different mouse models expressing ApoE4 with the ABCA1 agonist CS-6253 or the LXR agonist T0901317 have been shown to increase ApoE4 lipidation, as well as to reduce ApoE4-driven Aβ accumulation and cognitive deficits [71,72].”
From ApoE3 vs. ApoE4 Astrocytes: A Detailed Analysis Provides New Insights into Differences in Cholesterol Homeostasis (2022) · cites this paper as [72]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
The role of apolipoprotein E in Alzheimer's disease
Kim, J., Basak, J. M., & Holtzman, D. M. (2009) · Neuron · doi:10.1016/j.neuron.2009.06.026 · Cited by 1,661
Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance
Castellano, J. M., Kim, J., Stewart, F. R., Jiang, H., DeMattos, R. B., Patterson, B. W., Fagan, A. M., Morris, J. C., Mawuenyega, K. G., Cruchaga, C., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002156 · Cited by 1,242
ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models
Cramer, P. E., Cirrito, J. R., Wesson, D. W., Lee, C. Y. D., Karlo, J. C., Zinn, A. E., Casali, B. T., Restivo, J. L., Goebel, W. D., James, M. J., et al. (2012) · Science · doi:10.1126/science.1217697 · Cited by 1,050
ApoE Promotes the Proteolytic Degradation of Aβ
Jiang, Q., Lee, C. Y. D., Mandrekar, S., Wilkinson, B., Cramer, P., Zelcer, N., Mann, K., Lamb, B., Willson, T. M., Collins, J. L., et al. (2008) · Neuron · doi:10.1016/j.neuron.2008.04.010 · Cited by 876
ApoE and Aβ in Alzheimer’s Disease: Accidental Encounters or Partners?
Kanekiyo, T., Xu, H., & Bu, G. (2014) · Neuron · doi:10.1016/j.neuron.2014.01.045 · Cited by 608
Um, J. W., Kaufman, A. C., Kostylev, M., Heiss, J. K., Stagi, M., Takahashi, H., Kerrisk, M. E., Vortmeyer, A., Wisniewski, T., Koleske, A. J., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.06.036 · Cited by 572
Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease
Wahrle, S. E., Jiang, H., Parsadanian, M., Kim, J., Li, A., Knoten, A., Jain, S., Hirsch-Reinshagen, V., Wellington, C. L., Bales, K. R., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33622 · Cited by 370
Lack of ABCA1 Considerably Decreases Brain ApoE Level and Increases Amyloid Deposition in APP23 Mice
Koldamova, R., Staufenbiel, M., & Lefterov, I. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504513200 · Cited by 350
Self-citationFyn inhibition rescues established memory and synapse loss in Alzheimer mice
Kaufman, A. C., Salazar, S. V., Haas, L. T., Yang, J., Kostylev, M. A., Jeng, A. T., Robinson, S. A., Gunther, E. C., van Dyck, C. H., Nygaard, H. B., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24394 · Cited by 314
Koldamova, R. P., Lefterov, I. M., Staufenbiel, M., Wolfe, D., Huang, S., Glorioso, J. C., Walter, M., Roth, M. G., & Lazo, J. S. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m411420200 · Cited by 279
Self-citationHuman APOE Isoform-Dependent Effects on Brain β-Amyloid Levels in PDAPP Transgenic Mice
Bales, K. R., Liu, F., Wu, S., Lin, S., Koger, D., DeLong, C., Hansen, J. C., Sullivan, P. M., & Paul, S. M. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.0887-09.2009 · Cited by 274
Riddell, D. R., Zhou, H., Comery, T. A., Kouranova, E., Lo, C. F., Warwick, H. K., Ring, R. H., Kirksey, Y., Aschmies, S., Xu, J., et al. (2007) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2007.01.011 · Cited by 244
Hirsch-Reinshagen, V., Maia, L. F., Burgess, B. L., Blain, J.-F., Naus, K. E., McIsaac, S. A., Parkinson, P. F., Chan, J. Y., Tansley, G. H., Hayden, M. R., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m508781200 · Cited by 233
Expression of Liver X Receptor Target Genes Decreases Cellular Amyloid β Peptide Secretion
Sun, Y., Yao, J., Kim, T.-W., & Tall, A. R. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300760200 · Cited by 179
Fitz, N. F., Cronican, A. A., Lefterov, I., & Koldamova, R. (2013) · Science · doi:10.1126/science.1235809 · Cited by 151
Self-citationATP-binding cassette transporter A1: From metabolism to neurodegeneration
Koldamova, R., Fitz, N. F., & Lefterov, I. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.05.007 · Cited by 144
Self-citationKim, J., Yoon, H., Basak, J., & Kim, J. (2014) · Molecules and Cells · doi:10.14348/molcells.2014.0248 · Cited by 141 · cited 1×
“Synaptic dysfunction in AD pathogenesis is recognized as an important mechanism and the role of APOE in affecting synaptic plasticity in an isoform-dependent manner has been repeatedly confirmed (reviewed in [6, 47, 48]).”
Veeraraghavalu, K., Zhang, C., Miller, S., Hefendehl, J. K., Rajapaksha, T. W., Ulrich, J., Jucker, M., Holtzman, D. M., Tanzi, R. E., Vassar, R., et al. (2013) · Science · doi:10.1126/science.1235505 · Cited by 133
Tesseur, I., Lo, A. C., Roberfroid, A., Dietvorst, S., Van Broeck, B., Borgers, M., Gijsen, H., Moechars, D., Mercken, M., Kemp, J., et al. (2013) · Science · doi:10.1126/science.1233937 · Cited by 128
Nuclear receptors in neurodegenerative diseases
Skerrett, R., Malm, T., & Landreth, G. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.05.019 · Cited by 94
Lefterov, I., Bookout, A., Wang, Z., Staufenbiel, M., Mangelsdorf, D., & Koldamova, R. (2007) · Molecular Neurodegeneration · doi:10.1186/1750-1326-2-20 · Cited by 89
Self-citationBexarotene-Activated Retinoid X Receptors Regulate Neuronal Differentiation and Dendritic Complexity
Mounier, A., Georgiev, D., Nam, K. N., Fitz, N. F., Castranio, E. L., Wolfe, C. M., Cronican, A. A., Schug, J., Lefterov, I., & Koldamova, R. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.1001-15.2015 · Cited by 64
Self-citation
Flagged first, then by citations
Research works printed but not linked: 31
- EH Corder, 1993, Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families, Science (New York, NY), 261, 921, 10.1126/science.8346443 · DOI · Paper page
- NF Fitz, 2012, Abca1 deficiency affects Alzheimer's disease-like phenotype in human ApoE4 but not in ApoE3-targeted replacement mice, J Neurosci, 32, 13125, 10.1523/JNEUROSCI.1937-12.2012 · DOI · Paper page
- CM Karch, 2015, Alzheimer's disease risk genes and mechanisms of disease pathogenesis, Biol Psychiatry, 77, 43, 10.1016/j.biopsych.2014.05.006 · DOI · Paper page
- BA Benitez, 2014, Missense variant in TREML2 protects against Alzheimer's disease, Neurobiology of aging, 35, 1510, 10.1016/j.neurobiolaging.2013.12.010 · DOI
- LT Nordestgaard, 2015, Loss-of-function mutation in ABCA1 and risk of Alzheimer's disease and cerebrovascular disease, Alzheimer's & dementia: the journal of the Alzheimer's Association, 11, 1430, 10.1016/j.jalz.2015.04.006 · DOI · Paper page
- SE Wahrle, 2005, Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease, J Biol Chem, 280, 43236, 10.1074/jbc.M508780200 · DOI · Paper page
- I Lefterov, 2009, Memory deficits in APP23/Abca1+/- mice correlate with the level of Abeta oligomers, ASN NEURO, 1, 10.1042/AN20090015 · DOI
- JJ Donkin, 2010, ATP-binding cassette transporter A1 mediates the beneficial effects of the liver X receptor agonist GW3965 on object recognition memory and amyloid burden in amyloid precursor protein/presenilin 1 mice, The Journal of biological chemistry, 285, 34144, 10.1074/jbc.M110.108100 · DOI · Paper page
- N Zelcer, 2007, Attenuation of neuroinflammation and Alzheimer's disease pathology by liver x receptors, Proc Natl Acad Sci U S A, 104, 10601, 10.1073/pnas.0701096104 · DOI · Paper page
- RP Koldamova, 2003, 22R-hydroxycholesterol and 9-cis-retinoic acid induce ATP-binding cassette transporter A1 expression and cholesterol efflux in brain cells and decrease amyloid beta secretion, J Biol Chem, 278, 13244, 10.1074/jbc.M300044200 · DOI · Paper page
- A Boehm-Cagan, 2014, Reversal of apoE4-driven brain pathology and behavioral deficits by bexarotene, The Journal of neuroscience: the official journal of the Society for Neuroscience, 34, 7293, 10.1523/JNEUROSCI.5198-13.2014 · DOI · Paper page
- AR Price, 2013, Comment on "ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models", Science, 340, 924-d, 10.1126/science.1234089 · DOI · Paper page
- KD LaClair, 2013, Treatment with bexarotene, a compound that increases apolipoprotein-E, provides no cognitive benefit in mutant APP/PS1 mice, Mol Neurodegener, 8, 18, 10.1186/1750-1326-8-18 · DOI · Paper page
- KN Nam, 2016, RXR controlled regulatory networks identified in mouse brain counteract deleterious effects of Abeta oligomers, Sci Rep, 6, 24048, 10.1038/srep24048 · DOI
- JL Jankowsky, 2002, Transgenic mouse models of neurodegenerative disease: opportunities for therapeutic development, Current neurology and neuroscience reports, 2, 457, 10.1007/s11910-002-0073-7 · DOI
- NF Fitz, 2014, Improvement of memory deficits and amyloid-beta clearance in aged APP23 mice treated with a combination of anti-amyloid-beta antibody and LXR agonist, Journal of Alzheimer's disease: JAD, 41, 535, 10.3233/JAD-132789 · DOI
- AA Cronican, 2013, Genome-wide alteration of histone H3K9 acetylation pattern in mouse offspring prenatally exposed to arsenic, PloS one, 8, e53478, 10.1371/journal.pone.0053478 · DOI
- NF Fitz, 2015, Opposing effects of Apoe/Apoa1 double deletion on amyloid-beta pathology and cognitive performance in APP mice, Brain, 138, 3699, 10.1093/brain/awv293 · DOI
- AW Corona, 2015, ABCA1 is Necessary for Bexarotene-Mediated Clearance of Soluble Amyloid Beta from the Hippocampus of APP/PS1 Mice, J Neuroimmune Pharmacol
- VK Mootha, 2003, PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes, Nat Genet, 34, 267, 10.1038/ng1180 · DOI · Paper page
- AR Simard, 2006, Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease, Neuron, 49, 489, 10.1016/j.neuron.2006.01.022 · DOI · Paper page
- L Tuosto, 2015, The multifaceted role of PIP2 in leukocyte biology. Cellular and molecular life sciences, CMLS, 72, 4461, 10.1007/s00018-015-2013-0 · DOI
- BT Casali, 2015, Omega-3 Fatty Acids Augment the Actions of Nuclear Receptor Agonists in a Mouse Model of Alzheimer's Disease, J Neurosci, 35, 9173, 10.1523/JNEUROSCI.1000-15.2015 · DOI
- NF Fitz, 2010, Liver X receptor agonist treatment ameliorates amyloid pathology and memory deficits caused by high-fat diet in APP23 mice, J Neurosci, 30, 6862, 10.1523/JNEUROSCI.1051-10.2010 · DOI · Paper page
- T Vanmierlo, 2011, Liver X receptor activation restores memory in aged AD mice without reducing amyloid, Neurobiol Aging, 32, 1262, 10.1016/j.neurobiolaging.2009.07.005 · DOI · Paper page
- DJ Selkoe, 2002, Alzheimer's disease is a synaptic failure, Science, 298, 789, 10.1126/science.1074069 · DOI · Paper page
- CL McDonald, 2016, Inhibiting TLR2 activation attenuates amyloid accumulation and glial activation in a mouse model of Alzheimer's disease, Brain, behavior, and immunity, 58, 191, 10.1016/j.bbi.2016.07.143 · DOI · Paper page
- T Yagi, 2008, Clustered protocadherin family, Dev Growth Differ, 50, S131, 10.1111/j.1440-169X.2008.00991.x · DOI
- D Junghans, 2008, Postsynaptic and differential localization to neuronal subtypes of protocadherin beta16 in the mammalian central nervous system, Eur J Neurosci, 27, 559, 10.1111/j.1460-9568.2008.06052.x · DOI
- M Frank, 2005, Differential expression of individual gamma-protocadherins during mouse brain development, Mol Cell Neurosci, 29, 603, 10.1016/j.mcn.2005.05.001 · DOI · Paper page
- S Obata, 1995, Protocadherin Pcdh2 shows properties similar to, but distinct from, those of classical cadherins, J Cell Sci, 108, 3765, 10.1242/jcs.108.12.3765 · DOI
Cited by
Sorted by citations
Apolipoprotein E in lipid metabolism and neurodegenerative disease
Yang, L. G., March, Z. M., Stephenson, R. A., & Narayan, P. S. (2023) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2023.05.002 · Cited by 286
Litvinchuk, A., Suh, J. H., Guo, J. L., Lin, K., Davis, S. S., Bien-Ly, N., Tycksen, E., Tabor, G. T., Remolina Serrano, J., Manis, M., et al. (2024) · Neuron · doi:10.1016/j.neuron.2023.10.023 · Cited by 161
Trem2 deficiency differentially affects phenotype and transcriptome of human APOE3 and APOE4 mice
Fitz, N. F., Wolfe, C. M., Playso, B. E., Biedrzycki, R. J., Lu, Y., Nam, K. N., Lefterov, I., & Koldamova, R. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00394-4 · Cited by 68
Self-citationStaurenghi, E., Leoni, V., Lo Iacono, M., Sottero, B., Testa, G., Giannelli, S., Leonarduzzi, G., & Gamba, P. (2022) · Antioxidants · doi:10.3390/antiox11112168 · Cited by 24
Castranio, E. L., Wolfe, C. M., Nam, K. N., Letronne, F., Fitz, N. F., Lefterov, I., & Koldamova, R. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0569-2 · Cited by 23
Self-citation
Metadata
- Authors
- Carter, A. Y., Letronne, F., Fitz, N. F., Mounier, A., Wolfe, C. M., Nam, K. N., Reeves, V. L., Kamboh, H., Lefterov, I., & Koldamova, R.
- ORCID
- Lefterov, Iliya
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2017-02-27
- Volume
- 12
- Issue
- 2
- Pages
- e0172161
- ISSN
- 1932-6203
- PMC
- PMC5328633
- Cited by
- 28
- References
- 23
- Language
- en
- Funders
- National Institute of Environmental Health Sciences (ES024233)
- National Institute on Aging (AG037919, AG037481, K01AG044490)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
